N-Terminal Ubiquitination of Amyloidogenic Proteins Triggers Removal of Their Oligomers by the Proteasome Holoenzyme

Yu Ye1,2,3, David Klenerman2,4 and Daniel Finley1

1 - Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
2 - Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK
3 - UK Dementia Research Institute at Imperial College London, London W12 0NN, UK
4 - UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0XY, UK

Correspondence to Yu Ye: UK Dementia Research Institute at Imperial College London, London W12 0NN, UK
yu.ye1@imperial.ac.uk
https://doi.org/10.1016/j.jmb.2019.08.021

Edited by Ronald Wetzel

Aggregation of amyloidogenic proteins is an abnormal biological process implicated in neurodegenerative disorders. Whereas the aggregation process of amyloid-forming proteins has been studied extensively, the mechanism of aggregate removal is poorly understood. We recently demonstrated that proteasomes could fragment filamentous aggregates into smaller entities, restricting aggregate size [1]. Here, we show in vitro that UBE2W can modify the N-terminus of both α-synuclein and a tau tetra-repeat domain with a single ubiquitin. We demonstrate that an engineered N-terminal ubiquitin modification changes the aggregation process of both proteins, resulting in the formation of structurally distinct aggregates. Single-molecule approaches further reveal that the proteasome can target soluble oligomers assembled from ubiquitin-modified proteins independently of its peptidase activity, consistent with our recently reported fibril-fragmenting activity. Based on these results, we propose that proteasomes are able to target oligomers assembled from N-terminally ubiquitinated proteins. Our data suggest a possible disassembly mechanism by which N-terminal ubiquitination and the proteasome may together impede aggregate formation.

Introduction

The 26S proteasome holoenzyme is responsible for selective protein degradation in eukaryotic cells [2]. Proteins selected for degradation are often covalently modified with ubiquitin (Ub) moieties, which are recognized by the proteasome [2]. The proteolytic activity required for degradation is provided by the 20S core particle (CP) of the holoenzyme, whereas the 19S regulatory particle (RP) that caps the CP on one or both ends is responsible for substrate recognition and ATP-dependent substrate unfolding and translocation into the CP [3–5]. Many biological processes are dependent on the proteasome through controlled degradation of key regulatory factors, including homeostasis, unfolded protein response, and proteostasis [6]. An important role of proteasomes is to degrade damaged proteins, thereby preventing the accumulation of misfolded and amyloidogenic proteins, which have a propensity to form aggregates [7].

Aggregation of amyloidogenic proteins progresses through several stages, during which protein monomers assemble into soluble aggregates (oligomers) that through further aggregation events eventually undergo conformational rearrangement into filamentous aggregates (fibrils). The process of protein aggregation is harmful to normal cell physiology and is often associated with neurodegenerative disorders [8]. At the cellular level, accumulation of aggregates could be due to an increased rate of aggregation or decreased rate of aggregate removal, due to, e.g., changes in the ability to disassemble or degrade aggregates. Aggregates assembled from amyloidogenic proteins tau and α-synuclein (αS) have been implicated in Alzheimer disease (AD) and Parkinson disease (PD), respectively [9,10]. Both tau and αS are intrinsically disordered in their nonamyloid state as monomers and have been reported to be degradation-resistant as aggregates [11–14]. The inability to process certain aggregates may be coincident with proteasome malfunction, which in

0022-2836© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
certain brain regions of AD and PD patients have been reported with decreased activity [15,16]. We recently demonstrated that the mammalian proteasome holoenzyme possessed a fibril-fragmenting activity, reducing the size of large tau and zS fibrils into smaller entities in vitro [1]. Importantly, the proteasome catalyzed this fibril-fragmenting process in a Ub-independent manner. It is currently unclear how these smaller aggregate entities may be further processed by the cellular mechanisms. A recent study has further detailed the interactions of small soluble aggregated amyloidogenic proteins (oligomers) with the proteasome, which is markedly impaired by oligomer binding [17].

Studies in cells have indicated that monomeric tau and zS proteins could be degraded by the proteasome in a Ub-dependent manner [18–21], suggesting that aggregates of ubiquitinated proteins may accumulate when proteasomal functions are compromised. This assumption is supported by the observation of abundantly monoubiquitinated tau fibrils isolated from AD patient brain samples [22]. In addition, zS in the PD-associated Lewy bodies is also mainly monoubiquitinated [16,23]. Both tau and zS have dedicated Ub ligases, AXOT/MARCH7 [24] and SIAH1 [25,26], respectively, which preferentially monoubiquitinate their substrates. UBE2W, a Ub-conjugating enzyme that directly monoubiquitinates the N-terminus of intrinsically disordered proteins [27], has also been shown to modify tau [22,23]. Such N-terminal monoubiquitination is a well-defined degron recognized by the Ub-fusion degradation (UFD) pathway, which has been found in both yeast [28] and mammalian systems [29,30] to target misfolded proteins for proteasomal degradation and prevent cell stress. It is plausible to further hypothesize that aggregates assembled from N-terminal Ub-modified proteins would also recruit proteasomes for processing through the UFD pathway.

Here we show that the mammalian proteasome holoenzyme can target oligomers assembled from ubiquitinated tau aggregation domain (tauK18) and zS. We found that both tauK18 and zS may become ubiquitinated on the N-terminus by UBE2W. Using genetically engineered proteins with an N-terminal Ub moiety on tauK18 and zS, we demonstrated that such Ub modification delayed the aggregation process, which resulted in distinct aggregate structures compared with their unmodified counterparts. In addition, proteasomal functions were maintained in the presence of these Ub-modified aggregates. This was supported by data from single-molecule fluorescence spectroscopy experiments, which found a reduction in the number and the size of oligomers following proteasome treatment. The ability to target oligomers was not affected by Velcade-mediated inhibition of proteasomal proteolytic activity, suggesting that oligomer disassembly is not dependent on degradation. Based on these observations, we propose that N-terminal Ub modification on tau and zS enables proteasomes to target and remove oligomers assembled from these modified proteins.

**Results**

**N-terminal Ub modification on xS and tauK18 delays protein aggregation**

We chose to use full-length xS and a tetra-repeat domain of tau (tauK18) as model amyloidogenic proteins because both protein constructs have a similar molecular weight (~14 kDa, Fig. 1a). Using established protocols to purify untagged recombinant proteins of wild-type xS and tauK18 fragment, we found that both proteins could be ubiquitinated by UBE2W (Fig. 1b). The reaction did not continue beyond monoubiquitination as UBE2W specifically recognizes disordered sequences at the N-terminus of the substrate.

Protein ubiquitination by UBE2W did not reach completion after 2 h, resulting in a two-component mixture of Ub-modified and unmodified proteins. To obtain homogenous and pure Ub-modified xS and tauK18, we genetically engineered constructs that expressed fusion proteins with a single Ub moiety immediately before the first residue of xS or tauK18 (Ub-xS and Ub-tauK18; SFig. 1). These engineered N-terminal Ub-fusion proteins were protected from deubiquitination by a Gly76Ser substitution of the C-terminal residue of Ub. We further separately cloned the sequences of xS and tauK18 alone and purified these unmodified recombinant proteins using the same procedure as for the engineered Ub-modified proteins for consistency (see Materials and Methods).

Ub-xS and Ub-tauK18 were allowed to aggregate under similar conditions as their unmodified counterparts and measured by thioflavin T (ThT), which bound to β-sheet-rich amyloid structures. Unmodified xS entered an exponential phase reaching a half-saturated ThT intensity (t½) at ~11 h (Fig. 1c). In contrast, the aggregation of Ub-xS showed an extended lag phase and reached half-saturation with a delay of 14 h (t½ = 25 h). This Ub-dependent delay was even more apparent for Ub-tauK18 (estimated t½ of 96 h), whose aggregation was delayed by ~38 h compared with tauK18 (t½ = 58 h, Fig. 1d). These results suggest that Ub modification might decrease the rate of aggregate formation and/ or the level of total amyloid aggregates under our reaction conditions.

Aggregates assembled beyond 96 h were further imaged under TEM to qualitatively compare the effect of Ub modification. Interestingly, although
fibrils were detected from unmodified αS, those formed from Ub-αS mostly appeared as small amorphous assemblies (Fig. 2a). Despite repeated attempts, we could not detect any filamentous aggregates from Ub-αS under TEM. In comparison, Ub-modified tauK18 assembled into aggregates that appeared thinner and less filamentous-like than unmodified tauK18, which were detected abundantly (Fig. 2b). These results indicate that the morphology of filamentous aggregates is affected by N-terminal Ub modification.

**Single-molecule measurements of Ub-modified aggregates**

We previously established single-molecule fluorescence methods to measure the aggregation process independently of aggregate structure and...
to estimate the proportion of soluble aggregates (oligomers) [31–33]. In this study, we applied the same method and labeling strategy to attach fluorescent dyes to αS and tauK18 (SFig. 2a). Using this approach, we mixed the same protein labeled with Alexa488 or Alexa647 in a 1:1 stoichiometric ratio and initiated the aggregation reaction. Aggregate samples were flowed through a microfluidic channel and excited at suitable wavelengths with two overlapping lasers using a confocal microscope (SFig. 2b). Oligomers (here defined as 2-150mers) formed during aggregation will contain both dyes and give rise to coincident fluorescent bursts when they pass through the confocal volume of the laser (two color coincidence detection (TCCD)) [33], whereas any monomer signal will not give rise to coincident fluorescent bursts (Fig. 3a). The fraction of all fluorescence bursts that are coincident is proportional to the fraction of oligomers present and is measured by the association quotient \( Q \) (see Materials and Methods).

We could reproducibly detect oligomers from both tauK18 and Ub-tauK18 early in the aggregation process (Fig. 3b). The presence of tauK18 oligomers remained steady within the first 24 h, qualitatively consistent with our previously published results [32]. In comparison, Ub-tauK18 oligomers could be detected at a steady level up to 48 h from the start of aggregation reaction. An apparent reduction of the fraction of soluble oligomers with time was detected in both unmodified and Ub-modified tauK18 beyond 50 and 70 h, respectively. The loss of soluble oligomers as aggregation progresses had previously also been observed for tauK18 without Ub modification [32] and is likely due to the presence of aggregates that are either insoluble or too large to enter the microfluidic channel, hence not detected by single-molecule TCCD. The decrease in the calculated \( Q \) values were coincident with a reduction in the overall fluorescence signal measured, as the total number of dye labels passing through the volume has decreased, further supporting insoluble fibril formation.

A steady state population of soluble oligomers appeared in the aggregation of both unmodified and Ub-modified αS and did not change appreciably as the reaction proceeded over longer incubation times (Fig. 3c). Only a fraction of aggregates is therefore able to form ThT-active aggregate species, where the formation of Ub-modified αS aggregates is delayed compared with unmodified αS (shown in Fig. 1c). The ThT assays further suggest that there could be more β-sheet content in the aggregates formed from unmodified αS, as bulky Ub moieties may obstruct close packing of Ub-αS aggregates.
Proteasomes are able to target Ub-modified aggregates

To study the degradation of Ub-modified amyloidogenic proteins, we purified proteasome holoenzyme from an established mammalian cell line [34] using an affinity column (SFig. 3a). The purified proteasome holoenzyme was resolved and validated by SDS-PAGE (SFig. 3b), transmission electron microscopy (TEM, SFig. 3c) and native gel electrophoresis in the presence of an ATP-containing buffer (SFig. 3d). We could not quantitatively detect the presence of free proteasomal CPs with Coomassie staining or under TEM. A batch of the yeast proteasome holoenzyme was used as the molecular weight reference for the detection of capped and uncapped CP under similar conditions (SFig. 3e). All four Dye-labeled tauK18 and αS protein constructs could be quantitatively degraded by the proteasome, confirming their activity (SFig. 4a and b).

It has been reported that nonubiquitinated aggregates resist degradation [11–14], and both tau aggregates and αS oligomers have recently been shown to impede proteasome activity [13,17]. In addition, we recently demonstrated that the product...
of proteasome-catalyzed fragmenting of tau and αS fibrils was small aggregate entities, supporting our previous report that proteasomes had no effect on soluble αS oligomers without ubiquitin modification [39]. We therefore tested whether N-terminal Ub modification on tau and αS oligomers would enable their disassembly by proteasomes. ThT was found to bind to the proteasome, which interfered with fluorescence measurements (SFig. 4c). Turning to single-molecule TCCD approach, we reproducibly detected a decrease in the level of soluble oligomers in both Ub-tauK18 and Ub-αS as late as 96 h into the aggregation reaction (Table 1 shows a typical experiment). Ub-tauK18 oligomers generated throughout the assembly process were largely removed after incubation with the proteasome (Table 1a). The effect was also significant for oligomers assembled from Ub-αS, which decreased in the presence of the proteasome (Table 1b).

We previously used the relative fluorescence intensities of aggregates compared with monomers to calculate the apparent size of aggregates [31]. Analyzing the data in Table 1 revealed that the proteasome caused a general decrease in the aggregate level independently of the apparent aggregate size (STable 1), suggestive of gradual aggregate disassembly.

Our previous work using the same confocal single-molecule technique found that the proteasome did not target oligomers that are not modified with Ub [11] and that these oligomers are not affected by active chaperones [35]. We therefore attribute the observed reduction in aggregate level specifically to the proteasome. No change in the proteasomal proteolytic or the ATP-dependent activity after incubation with Ub-modified oligomers was observed (Fig. 4a and b), consistent with observations after incubating proteasomes with fibrils [1].

The fibril-fragmenting activity of the proteasome was shown to be independent of the peptidase activity [1]. To test whether the disassembly of Ub-modified oligomers also did not rely on the proteasomal peptidase activity, we repeated the single-molecule experiments using proteasomes that were preincubated with Velcade as in [1]. The decrease in Ub-tauK18 or Ub-αS oligomers was not affected by Velcade-mediated inhibition (Fig. 4c and d), consistent with our recent observation [1].

The ability of proteasomes to target Ub-modified oligomers was further resolved by Western blotting. Oligomers assembled from both Ub-tauK18 and Ub-αS were prone to proteasomal activity (SFig. 5a and c), whereas oligomers assembled from unmodified tauK18 and αS showed no detectable intensity change in the presence or absence of proteasome treatment (SFig. 5b and d). This is consistent with our hypothesis that oligomers formed from proteins N-terminally modified with Ub can be targeted by the proteasome, whereas unmodified oligomers remain unchanged.

**Discussion**

Our current work has shown that the presence of an N-terminal Ub moiety on tauK18 and αS results in distinct aggregation kinetics and aggregate conformations. Oligomers assembled from these Ub-modified proteins are prone to proteasomal activity. We previously demonstrated that proteasomes are

| Table 1. Representative TCCD experiments of proteasomal degradation of (a) Ub-tauK18 and (b) Ub-αS aggregates, respectively, illustrating how the single-molecule data were analyzed (see STable 1 for aggregate size dependency analysis). The experiments were performed in triplicate (see Fig. 4 for average results of repeat experiments). At the indicated times after aggregation initiation (first column), the number of aggregates were counted after incubation with either the control buffer (second column) or with the proteasome (third column). The calculated percentage reduction of aggregates is shown (fourth column).

| Aggregation time | Number of oligomers control | Number of oligomers + proteasome | Oligomer loss |
|------------------|-----------------------------|---------------------------------|--------------|
| 4                | 1053                        | 57                              | 95%          |
| 24               | 9802                        | 561                             | 94%          |
| 48               | 5670                        | 318                             | 94%          |
| 72               | 2880                        | 1676                            | 42%          |
| 96               | 278                         | 98                              | 65%          |

| Aggregation time | Number of oligomers control | Number of oligomers + proteasome | Oligomer loss |
|------------------|-----------------------------|---------------------------------|--------------|
| 4                | 6480                        | 1582                            | 76%          |
| 24               | 2930                        | 660                             | 77%          |
| 48               | 2158                        | 840                             | 61%          |
| 72               | 1737                        | 946                             | 46%          |
| 96               | 3726                        | 1875                            | 50%          |
able to target fibrils, as they are structurally distinct from nonfilamentous aggregates. This study further complements our previous demonstration of proteasomal fibril-fragmenting activity [1] with an additional proteasomal ability to target Ub-modified oligomers. Intriguingly, size analysis of oligomers at various times of aggregation did not indicate any clear trends in their susceptibility to be removed by proteasomes (Table 1), possibly suggesting that the gradual disassembly of oligomers may not be a straightforward process.

As tight assembly and packing are key features of amyloid aggregates, presence of a Ub moiety at the N-terminus could potentially induce soluble...
oligomers into a conformation distinct from unmodified protein aggregates. In another of our previous work, we found that arachidonic acid could induce a conformational change in soluble αS oligomers that could subsequently be targeted by the proteasome [11], suggesting that the proteasome acted more effectively on induced than uninduced oligomers, which contained more compact structures.

N-terminal monoubiquitination is associated with enzymes of the UFD pathway, which have been found in mammalian systems to target misfolded proteins [29,30] and foreign particles [36] for proteasomal degradation to prevent cell stress. Our current study demonstrates that such N-terminally monoubiquitinated proteins may assemble into soluble oligomers, which are distinct to aggregates assembled from proteins ubiquitinated on Lys residues [25,26,37–39]. As demonstrated here, N-terminally modified oligomers may be efficient proteasomal targets that exist transiently in cells and could therefore have escaped detection in traditional mass spectrometry analyses. The development of antibodies specific for N-terminal monoubiquitination [36] and a dedicated mass spectrometry proteomics approach [40] will likely provide additional insights into this unique ubiquitination type.

The complete monoUb modification on every protein within each oligomer in our study may provide avid recognition in vitro and enhance their disassembly efficacy at the proteasome. Physiologically, ubiquitination levels of tau and αS are likely to be dynamically regulated through both protein synthesis and degradation. Ub modifications on different positions within the proteins have distinct consequences for their aggregation properties. Our current study proves a novel concept of how N-terminal Ub modification impedes aggregation, enables proteasomes to target oligomers, and provides a possible option for oligomer disassembly by the ubiquitin-proteasome system.

Material and Methods

Molecular biology of plasmids for protein expression

A single Ub moiety was expressed in tandem to the protein of interest (ταK18 or αS). The DNA sequence of Ub was introduced either at the 5’ end, immediately before the ATG codon. When the Ub coding sequence was cloned upstream of the wild-type αS or ταK18 coding sequences, a mutation corresponding to Gly to Ser was introduced at residue 76, the last residue of Ub. The constructs were subsequently subcloned into a pOPINF vector using restriction enzymes, resulting in a His6-tag at the N-terminus of the Ub. TaupK18 or αS sequences were also separately cloned into the pOPINF vector without the Ub sequence, so that the His6-tag is immediately N-terminal to the substrate.

Cys mutations were introduced using site-directed mutagenesis on Ala90 of αS or Ile202 of τα (annotation based on the ON4R isoform sequence). We previously showed that introduction of Cys and subsequent dye-labeling did not disrupt the integrity and aggregation properties of these proteins [31,32]. Equivalent mutations were separately introduced into Ub−αS and Ub−ταK18 constructs. The two other Cys residues in wild-type ταK18 sequence were mutated to Ala [32].

The full-length sequence of mouse E1 in pET28a vector (kind gift from David Komander) and human UBE2W in pET15b vector (kind gift from Wade Harper, Addgene plasmid #15809) were used for protein expression. Plasmids for protein expression of full-length αS in pT7-7 vector or ταK18 sequence in pJExpress vector (custom designed) alone coded for untagged constructs of the wild-type sequence of human αS or ταK18. These untagged constructs coded for wild-type sequences of the N-terminal residues used in the ubiquitination assay by UBE2W.

Recombinant protein purification

Plasmids were transformed into Rosetta2 (DE3) pLysS cells (Novagen) and grown in LB media to OD600 = 1.0 before overnight induction with 1 mM IPTG at 20°C. Cells were collected the next day by centrifugation at 5000 × g for 30 min before lysis by sonication. The cell lysate was cleared by centrifugation at 21,000 × g for 30 min at 4°C.

The supernatant from purification of His6-tagged proteins was loaded onto a self-packed cobalt column (Clontech). Unbound proteins were washed off with Loading Buffer (50 mM Tris–HCl [pH 7.4], 100 mM NaCl, 10 mM imidazole), and bound proteins subsequently eluted with Elution Buffer (50 mM Tris–HCl, 100 mM NaCl, 200 mM imidazole, pH adjusted to 7.4).

Preparation of the supernatant from purification of untagged αS and ταK18 followed established protocols (e.g. Refs. [31,41]). In brief, the cleared supernatant was poured into a 50-ml falcon tube and incubated in boiling water for 10 min before cooling down to room temperature. The solution was cleared with a second centrifugation step at 21,000 × g for 30 min at 4°C, and the supernatant was filtered before further purification.

The eluted or filtered samples were further purified using ion exchange (IEX) chromatography columns HiTrapQ (for αS constructs) or HiTrapS (for tau constructs), running a linear NaCl gradient from Buffer A (50 mM Tris–HCl [pH 7.4], 50 mM NaCl) to 1 M NaCl. Peak fractions from the IEX were concentrated to <4 ml and loaded onto a Superdex 16/60 gel filtration column (GE Healthcare) in Buffer A. Eluted fractions were separated by SDS-PAGE, and fractions judged to be >99% pure by Coomassie stain were further concentrated and flash frozen in aliquots (SFig. 1). Protein concentrations were measured on a NanoDrop.

Dye-labeling on proteins

Proteins carrying Cys substitutions were dialyzed into Labeling Buffer (50 mM Tris–HCl [pH 7.2]) before dye-labeling. AlexaFluor 488 C5 maleimide or AlexaFluor 647 C2 maleimide (Invitrogen) were dissolved in DMSO and
added to the proteins in a 1:1.2 stoichiometric ratio of excess dye. We routinely use this protocol to ensure that essentially all proteins are labeled as detected by ion exchange chromatography, size exclusion chromatography, and mass spectroscopy. The labeling reaction was quenched after 1 h with fresh DTT at 100 mM final concentration and loaded onto a HiPrep 26/10 desalting column (GE Healthcare). The final labeled proteins were concentrated to at least 80 μM and flash frozen in Protein Buffer (50 mM Tris–HCl [pH 7.2], 50 mM NaCl, 0.01% Tween20) in small aliquots. Concentrations were determined by NanoDrop.

Purification of mammalian proteasomes

Proteasomes were purified from a HEK293T cell line stably expressing an Rpn11-TEV-Biotin tag (kind gift of Lan Huang, UC Irvine) using established protocols [34]. Briefly, cells were grown to 100% confluence and collected with a scraper before resuspension in ice-cold Proteasome Buffer (50 mM Tris [pH 7.5], 0.5% NP-40, 10% glycerol, 5 mM ATP, 1 mM DTT, 5 mM MgCl2). A Dounce homogenizer was then used to lyse the cells, and the lysate was cleared by centrifugation at 3000 g for 5 min at 4 °C. The lysate was incubated overnight at 4 °C in 2-mL bed volume of preequilibrated NeutrAvidin resin beads (Pierce). Unbound proteins were washed off with 2-ml bed volume of preequilibrated NeutrAvidin resin beads (Pierce). Unbound proteins were washed off with Proteasome Buffer. Proteasomes was subsequently released from the column with TEV protease (Invitrogen) at 30 °C and concentrated to >2 μM before flash freezing.

UBE2W ubiquitination assays

Ubiquitination assays were carried out at 25 °C in Ubiquitination Buffer (50 mM Tris [pH 7.5], 10 mM ATP, 1 mM DTT, 10 mM MgCl2), containing 0.5 μM of E1, 1 μM of UBE2W, 200 of μM wild-type Ub (Sigma), and 10 μM of untagged αS or tauK18 substrate. The reactions were incubated for 2 h before quenching by Laemmli Buffer containing reducing agent. Substrates were excluded in control samples to test for cross-reactivity of the antibodies used with the ubiquitinating enzymes or the Ub (Fig. 1b).

Protein aggregation assays

For protein aggregation, Ub-tauK18 or tauK18 were diluted in PBS Buffer (MP Biomedicals) containing 0.01% sodium azide to 10 μM final concentration and incubated at 37 °C. An equimolar amount of heparin (H3393, Sigma-Aldrich) was added to initiate tauK18 aggregation reactions. Aggregation assays for Ub-αS or αS were performed at 40 μM final protein concentration in PBS Buffer containing 0.01% sodium azide and incubated at 37 °C shaking, as described [31]. We did not detect pellets of insoluble fibrils after 10 min centrifugation at 13,000 × g for Ub-tauK18 or Ub-αS aggregates.

Thioflavin T fluorescence assays

Thioflavin T (Sigma) was dissolved in PBS and filtered through a 0.02 μM filter. The concentration was determined by UV absorbance at 405 nm on a NanoDrop. Aliquots were removed from tauK18 (10 μl) or αS (5 μl) samples at indicated times after aggregation initiation and mixed with 40 μl of the ThT solution at 10 μM. The mixture was incubated for 10 min and subsequently measured on a spectrophotometer (λex = 415 nm, Varian Eclipse). Integral area between 460 and 560 nm of the emission spectrum was calculated for each time point. The mean value of triplicate aggregation assays was used to plot Fig. 1c and d. Each data set was fitted to a sigmoidal function, defined as

\[
\text{Intensity}_{\text{ThT}} = \frac{1}{1 + \left(\frac{t}{t_{\text{half}}}\right)^{\beta}}
\]

where \(t\) is the time after aggregation initiation in hrs and \(\text{Intensity}_{\text{ThT}}\) is the mean integral area of fluorescence emission. All plots were calculated and generated using IgorPro (WaveMetrics). The sigmoidal behavior of aggregation produces the time, \(t_{\text{half}}\), needed for \(\text{Intensity}_{\text{ThT}}\) to reach 50% of the maximal plateau value.

Degradation assays

Degradation assays were typically performed at 25 °C in Degradation Buffer (50 mM Tris–HCl [pH 7.5], 10 mM ATP–MgCl2, 30 mM creatine phosphate, 4 μM creatine kinase) containing 40 nM proteasome. Control samples were set up in the same buffer without adding the proteasome. TauK18 substrates were reacted for 3 h at a final concentration of 2.6 μM in PAGE-based assays and 0.2 μM in single-molecule assays. Incubation time for αS samples was 12 h and diluted to a final concentration of 10 μM in PAGE-based assays and 1 μM in single-molecule assays. We occasionally observe secondary dimer or higher bands emerging with prolonged incubation when the substrate concentration is higher than 10 μM, indicating sporadic aggregation during degradation assays. For the inhibitor assays, the proteasome was preincubated for 5 min at 25 °C with Velcade (Proteasome Velcade) to a final concentration of 100 μM.

Resolving of aggregate samples by gel electrophoresis and Western blotting

Proteasomes used in the overnight degradation assays were resolved on self-poured 3% polyacrylamide native gels and detected with a fluorogenic model substrate, LLVY-AMC, as described previously [42]. For Western blotting, protein samples were first separated on 4–12% NuPAGE gels (Invitrogen) and then transferred to PVDF membranes as per manufacturer’s protocol (Mini Trans-Blot wet transfer, Biorad). Samples taken were quenched with Lammeli buffer but not heated (to preserve the oligomeric bands). Mouse anti-tau (1E1/A6, Merck) or rabbit anti-αS (ab138501, Abcam) were used as primary antibodies following standard Western blotting methods. Secondary anti-mouse and anti-rabbit antibodies compatible with detection on an Odyssey CLx Imager or a Typhoon scanner were purchased from Li-Cor or Invitrogen.

Proteasomes Remove N-Terminal Ubiquitinated Tau and α-Synuclein Oligomers 593
Colorimetric phosphate assay

ATPase kit containing malachite green and ammonium molybdate was purchased from Abcam (ab65622). For assays in Figs. 4b, 40 μl of each reaction (set up as described in Degradation assays section) was mixed with 6 μl of the malachite green reagent and incubated for 15 min before measurement. The colorimetric output was measured at OD = 650 nm on a microplate reader. A linear standard curve from 0 to 20 mM of free phosphates was established to convert colorimetric reading into phosphate concentration. Three independent replicate experiments were performed for each reaction.

Transmission electron microscopy imaging

Samples shown in Fig. 2 were aggregated beyond 96 h and applied onto a carbon-coated 400 mesh copper grid (Agar Scientific). Mammalian proteasome was applied at 100 nM concentration. The grids were then washed with double distilled water and stained with 2% (w/v) uranyl acetate for 1 min. TEM images were acquired using Tecnai G2 microscope (13218, EDAX, AMETEK) operating at an excitation voltage of 200 kV.

Single-molecule measurements

The instrument setup and collection of single-molecule data are based on our earlier works and have been extensively described (e.g., Refs. [31, 43]). Briefly, single-molecule data were collected on a custom-built system using overlapping lasers with excitation maxima at 485 nm and 640 nm (see SFig. 2a). The rate of modulation for both lasers was at 10 modulations per millisecond. Samples were measured under flow using custom-made PDMS microfluidics devices following published procedures [45]. Aggregates were assembled from protein monomers labeled with either AlexaFluor 488 or AlexaFluor 647 and mixed in a 1:1 stoichiometric ratio for aggregation (SFig. 2a). This ensures that only aggregates will carry both dyes and will be detected by the coincidence criterion [33].

Degradation assays were performed for 3 h (Ub-tauK18, or 12 h (Ub-αS) and diluted for immediate single-molecule measurement. Fluorescent protein samples were diluted to 100 pM (Ub-αS) or 40 pM (Ub-tauK18) final concentration and measured under flow according to previously established methods [32, 44]. The bin time and flow rates for Ub-αS and Ub-tauK18 constructs were individually optimized to achieve the highest value of Q as described previously [11, 32]. Ub-αS aggregates were measured at 100 μl/h flow rate, and the fluorescence signals were collected with 0.1 ms bin time. For Ub-tauK18 samples, the flow rate and bin time were 50 μl/h and 0.2 ms, respectively. Data were typically collected for 15 min at 25 ºC in frames of 50,000 bins. Independent triplicate experiments were performed for Ub-tauK18 and Ub-αS aggregation reactions. A representative set of aggregate degradation measurements is shown in Table 1.

Single-molecule data analysis

We used the AND criterion to detect coincidence events in the two channels [33]. This separates aggregation events from background monomers by accepting only those signals for which the blue- and the red-excited channels are above the threshold value. The proportion of monomers that are associated to form oligomers is expressed using the association quotient Q, which is defined as

\[
Q = \frac{C - AB \tau}{A + B - (C - AB \tau)} \times 100\%
\]

where A and B are the rates of detection of events in the two fluorescent channels, respectively, and C is the detection rate of coincident events; \(\tau\) is the interval time of detection so that the AB\(\tau\) expresses the coincident events that occur by chance [33]. We also measured the level of background detection of the buffer containing no fluorescent proteins and applied a uniform threshold fivefold over the background in both red- and blue-detector channels (10 KHz) to remove noise signals. We found, in a previous work using this method, good agreement between size distribution of particles immobilized onto a surface and those measured in solution of the same particles [44], showing that potential laser beam inhomogeneity will not become a significant effect in these experiments. A reference duplex DNA sample of 40 base pairs labeled with AlexaFluor 488 and AlexaFluor 647 at the 5’ end of each of the single DNA strands, repeatedly gave a Q value of 30%, using the same analysis [43].

Each single-molecule measurement was normalized to a standard number of frames, and the number of significant coincident events was counted. The percentage decrease in oligomers upon proteasome treatment is calculated as follows:

\[
decrease = \frac{aggregate_{ctrl} - aggregate_{ptsm}}{aggregate_{ctrl}}
\]

which is expressed in percentage. The estimation of apparent aggregate size was carried out as previously described [31], based on the fluorescence intensities of each aggregate as it passed through the probe volume. In brief, the approximate monomer number per aggregate can be extracted assuming that 50% of monomers are donors using the equation

\[
Aggregate\ size = \frac{I_{DA} + I_{A}/\gamma}{I_{D,monomer}}
\]

where \(I_{DA}\) represents the donor fluorescence intensity in presence of acceptor, \(I_{A}\) the acceptor fluorescence intensity, \(I_{D,monomer}\) corresponds to the average intensity of donor monomers, and \(\gamma\) to a correction factor that accounts for different quantum yields and detection efficiencies of the donor and acceptor.

Previous control experiments on αS aggregates showed that this analysis recovered the same apparent size distribution as that measured when the aggregates were immobilized on a glass surface [44]. Depending on the calculated apparent aggregate size, each aggregate was subsequently arbitrarily classified either as small (size ≤ 15), medium (size 16–30), or large (size 31–45), and the frequency of each group reported as in STable 1.
Acknowledgments

The authors would like to thank members of the D.K. and D.F. laboratories for reagents and helpful discussions. This research is funded by a Sir Henry Wellcome Research Fellowship awarded to Y.Y. Research carried out in DF’s laboratory is funded by NIH grant R01 GM043601 and a grant from the Rainwater Foundation.

Author Contributions

D.F. and D.K. directed the research. D.F., D.K. and Y.Y. designed the experiments. Y.Y. conceptualized the project, performed the experiments, analyzed the data, and prepared the manuscript. All authors contributed to the writing of the manuscript.

Declarations

The authors declare that they have no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jmb.2019.08.021.

Received 19 June 2019;
Received in revised form 29 August 2019;
Accepted 30 August 2019
Available online 10 September 2019

References

[1] R. Cliffe, J.C. Sang, F. Kundel, D. Finley, D. Klenerman, Y. Ye, Filamentous aggregates are fragmentized by the proteasome, Holoenzyme 26 (2019), https://doi.org/10.1016/j.celrep.2019.01.086, 2140–2149.e3.
[2] D. Komander, M. Rape, The ubiquitin code, Annu. Rev. Biochem. 81 (2012) 203–229, https://doi.org/10.1146/annurev-biochem-060310-170328.
[3] X. Huang, B. Luan, J. Wu, Y. Shi, An atomic structure of the human 26S proteasome, Nat. Struct. Mol. Biol. (2016), https://doi.org/10.1038/nsmb.3273.
[4] A. Schweitzer, A. Aufderheide, T. Rudack, F. Beck, G. Pfeifer, J.M. Plitzko, et al., Structure of the human 26S proteasome at a resolution of 3.9 Å, Proc. Natl. Acad. Sci. 113 (2016) 7816–7821, https://doi.org/10.1073/pnas.1608050113.
[5] M.E. Matyskiela, G.C. Lander, A. Martin, Conformational switching of the 26S proteasome enables substrate degradation, Nat. Struct. Mol. Biol. (2013), https://doi.org/10.1038/nsmb.2616.
[6] E.M. Sontag, R.S. Samant, J. Frydman, Mechanisms and functions of spatial protein quality control, Annu. Rev. Biochem. 86 (2017) 97–122, https://doi.org/10.1146/annurev-biochem-060815-014616.
[7] N. Berner, K.-R. Reutter, D.H. Wolf, Protein quality control of the endoplasmic reticulum and ubiquitin-proteasome-triggered degradation of aberrant proteins: yeast pioneeers the path, Annu. Rev. Biochem. 87 (2018) 751–782, https://doi.org/10.1146/annurev-biochem-062917-012749.
[8] J. Vaquer-Alicea, M.I. Diamond, Propagation of protein aggregation in neurodegenerative diseases, Annu. Rev. Biochem. 88 (2019) 785–810, https://doi.org/10.1146/annurev-biochem-061516-045049.
[9] A. Abeliovich, A.D. Gitler, Defects in trafficking bridge Parkinson's disease pathology and genetics, Nature 539 (2016) 207–216, https://doi.org/10.1038/nature20414.
[10] Y. Wang, E. Mandelkow, Tau in physiology and pathology, Nat. Rev. Neurosci. 17 (2016) 5–21, https://doi.org/10.1038/nrn.2015.1.
[11] M. Iljin, L. Tosatto, M.L. Choi, J.C. Sang, Y. Ye, C.D. Hughes, et al., Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein, Sci. Rep. 6 (2016) 33928, https://doi.org/10.1038/srep33928.
[12] S.A. Tanik, C.E. Schultheiss, L.A. Volpicelli-Daley, K.R. Brunden, V.M.Y. Lee, Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy, J. Biol. Chem. 288 (2013) 15194–15210, https://doi.org/10.1074/jbc.M113.457408.
[13] N. Myeku, C.L. Clelland, S. Emrani, N.V. Kukushkin, W.H. Yu, A.L. Goldberg, et al., Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling, Nat. Med. 22 (2016) 46–53, https://doi.org/10.1038/nm.4011.
[14] S. Keck, R. Nitsch, T. Grune, Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease, J. Neurochem. 85 (2003) 115–122.
[15] J.N. Keller, K.B. Hanni, W.R. Markesbery, Impaired proteasome function in Alzheimer’s disease, J. Neurochem. 75 (2000) 436–439.
[16] G.K. Tofaris, A. Razzaz, B. Ghetti, K.S. Lilley, M.G. Spillantini, Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function, J. Biol. Chem. 278 (2003) 44405–44411, https://doi.org/10.1074/jbc.M308041200.
[17] T.A. Thibaudeau, R.T. Anderson, D.M. Smith, A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers, Nat. Commun. 9 (2018) 1097, https://doi.org/10.1038/s41467-018-03509-0.
[18] B.-H. Lee, M.J. Lee, S. Park, D.-C. Oh, S. Elsasser, P.-C. Chen, et al., Enhancement of proteasome activity by a small-molecule inhibitor of USP14, Nature 467 (2010) 179–184, https://doi.org/10.1038/nature09299.
[19] H.-J. Lee, F. Khoshaghideh, S. Patel, S.-J. Lee, Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway, J. Neurosci. 24 (2004) 1888–1896, https://doi.org/10.1523/JNEUROSCI.3809-03.2004.
[20] D.H. Han, H.-K. Na, W.H. Choi, J.H. Lee, Y.K. Kim, C. Won, et al., Direct cellular delivery of human proteasomes to delay tau aggregation, Nat. Commun. vol. 5 (2014) 5633, https://doi.org/10.1038/ncomms6633.
Phosphorylated alpha-synuclein is ubiquiti-